

REFERENCE

- André, P. *et al.* (2002) 'Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles', *Journal of Virology*, 76(14), pp. 6919–6928. doi: 10.1128/JVI.76.14.6919.
- Ashfaq, U. A. *et al.* (2011a) 'An overview of HCV molecular biology, replication and immune responses', *Virology Journal*, 8(Figure 1), pp. 1–10. doi: 10.1186/1743-422X-8-161.
- Ashfaq, U. A. *et al.* (2011b) 'An overview of HCV molecular biology, replication and immune responses', *Virology Journal*, 8(1), p. 161. doi: 10.1186/1743-422X-8-161.
- Brahim S, Akil A, Mtairag el M, Pouillot R, Malki AE, Nadir S *et al* (2012) Morocco underwent a drift of circulating hepatitis C virus subtypes in recent decades. *Arch Virol* 157:515–520
- Cacoub, P. *et al.* (2014) 'Extrahepatic manifestations of chronic hepatitis C virus infection', *Digestive and Liver Disease*, 46(S5), pp. S165–S173. doi: 10.1016/j.dld.2014.10.005.
- Chevaliez, S. and Asselah, T. (2011) 'Mechanisms of non-response to antiviral treatment in chronic hepatitis C.', *Clinics and research in hepatology and gastroenterology*. Elsevier, 35 Suppl 1, pp. S31–S41. doi: 10.1016/S2210-7401(11)70005-5.
- Chopra, S. (2019). *Characteristic of Hepatitis C Virus*. [online] Uptodate.com. Available at: https://www.uptodate.com/contents/characteristics-of-the-hepatitis-c-virus?sectionName=Genotypes&search=HCV%20has%2011%20genotypes%20with%20several%20different%20subtypes&topicRef=15832&anchor=H5&source=see_link%23H5 [Accessed 1 Oct. 2019].
- Consensus, N. I. H. and Statements, S. (2002) 'NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consensus and State-of-the-Science Statements', 19(3), p. 52. Available at: <http://consensus.nih.gov>.
- Dhawan, V. and Anand, B. (2019). *Hepatitis C Treatment & Management: Approach Considerations, Interferons and Pegylated Interferons, Interferons and Ribavirin*. [online] Emedicine.medscape.com. Available at: <https://emedicine.medscape.com/article/177792-treatment> [Accessed 1 Oct. 2019].
- Ebid, A., Mobarez, M., Adel, M. and Ramadan, R. (2017). Pegylated Interferon, Ribavirin, and Sofosbuvir Combination versus Pegylated Interferon, Ribavirin in the Management of Chronic Hepatitis C Egyptian Patients. *Journal of Advanced Pharmacy Research*, 1(1), pp.25-33.
- Hansen, N. *et al.* (2011) 'Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study', *BMC Infectious Diseases*, 11. doi: 10.1186/1471-2334-11-177.
- Irshad, M., Mankotia, D. S. and Irshad, K. (2013) 'An insight into the diagnosis and pathogenesis of hepatitis C virus infection', *World Journal of Gastroenterology*, 19(44), pp. 7896–7909. doi: 10.3748/wjg.v19.i44.7896.
- Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F (2013) Distribution of hepatitis C virus genotypes in Iranian chronic

- infected patients. *Hepat Mon* 13: e7991
- Jazwinski, A. B. and Muir, A. J. (2011) 'Direct-acting antiviral medications for chronic hepatitis C virus infection', *Gastroenterology and Hepatology*, 7(3), pp. 154–162.
- Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S., *et al.* (2013). Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. *New England Journal of Medicine*, 368(20), pp.1878-1887.
- Liang, T. J. *et al.* (2000) 'Pathogenesis, natural history, treatment, and prevention of hepatitis C', *Annals of Internal Medicine*, 132(4), pp. 296–305. doi: 10.7326/0003-4819-132-4-200002150-00008.
- Liu, T., Sha, K., Yang, L., Wang, Y., Zhang, L., Liu, X. and Yang, F. (2014). IL-28B Polymorphisms Correlated with Treatment Response in HCV-4 Mono-Infected Patients: A Meta-Analysis. *PLoS ONE*, 9(3), p.e91316.
- Neumann, A. U. *et al.* (1998) 'Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- α therapy', *Science*. doi: 10.1126/science.282.5386.103
- Niu, Z., Zhang, P. and Tong, Y. (2016). Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. *SpringerPlus*, 5(1).
- Palumbo, E. (2011) 'Pegylated interferon and ribavirin treatment for hepatitis C virus infection', *Therapeutic Advances in Chronic Disease*, 2(1), pp. 39–45. doi: 10.1177/2040622310384308.
- Pawlotsky, J. M. (2004) 'Pathophysiology of hepatitis C virus infection and related liver disease', *Trends in Microbiology*, 12(2), pp. 96–102. doi: 10.1016/j.tim.2003.12.005.
- Pawlotsky, J. M. *et al.* (2018) 'EASL Recommendations on Treatment of Hepatitis C 2018', *Journal of Hepatology*. European Association for the Study of the Liver, 69(2), pp. 461–511. doi: 10.1016/j.jhep.2018.03.026.
- Petruzzello, A. *et al.* (2016) 'Global epidemiology of hepatitis C virus infection: An update of the distribution and circulation of hepatitis C virus genotypes', *World Journal of Gastroenterology*, 22(34), pp. 7824–7840. doi: 10.3748/wjg.v22.i34.7824.
- Rouabhia S, Sadelaoud M, Chaabna-Mokrane K, Toumi W, Abenavoli L (2013) Hepatitis C virus genotypes in north eastern Algeria: a retrospective study. *World J Hepatol* 5:393–397
- Sezaki, H., Suzuki, F., Kawamura, Y., Yatsuji, H., Hosaka, T., Akuta, N., . Kumada, H. (2009). Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. *Digestive Diseases and Sciences*, 54(6), 1317–1324.
- Simoes, P., Asaad, A., Abed, J., Engelson, E. and Kotler, D. (2015). Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population. *Women's Health Issues*, 25(3), pp.289-293.
- Wait, S. *et al.* (2016) 'Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments', *The Lancet Gastroenterology and Hepatology*. Elsevier Ltd, 1(3), pp. 248–255. doi: 10.1016/S2468-1253(16)30031-0.
- Wyles DL, Gutierrez JA (2014) Importance of HCV genotype 1 subtypes for drug

resistance and response to therapy. *J Viral Hepat* 21:229–240
Zeuzem, S. (2017) ‘Treatment options in hepatitis C - The current state of the art’,
Deutsches Arzteblatt International, 114(1–2), pp. 11–21. doi:
10.3238/arztebl.2017.0011.